# Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

> **NCT00402025** · PHASE1 · COMPLETED · sponsor: **BioVex Limited** · enrollment: 17 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Talimogene Laherparepvec

## Key facts

- **NCT ID:** NCT00402025
- **Lead sponsor:** BioVex Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402025, "Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00402025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*